Antibe Therapeutics Inc(Pre-Merger) T.ATE

comgrats

[woundedknee]

Congrats to all longs that held on. Especially Mugsy. To all newbies and potential newbies just heads up. Keep tabs on insiders, as a couple in the past have sold a substantial amount just before bad news.
Hopefully this time around it will be different. gl

[MrMugsy]

Thanks Woundedknee. Just a waiting game now !!!!

[Hideaway]

Some waiting game.Close to 40% drop in past week.

[WalkOverTheStrt]

Have any insiders sold in the past month? 

[MrMugsy]

I hope you are just kidding WalkOverTheStrt. That question will never lead to understanding the drug, the true value of the drug or where P2 and P3 are going. I know that many use that as a barometer of where any company is going - but - we are way past that discussion. It's going to be about the following ... - Nuance resolution - P2 planning - Chronic path - new molecules - breakthrough

[WalkOverTheStrt]

Mugs I don't have a high view of Dan so I look at his sales of stock as a potential indicator, a data point. If mgmt bought on the open market that would be a nice sign of confidence.  I'll call out from your list the new molecule effort is a poor strategy by mgmt. They have for five plus years spent capital on trying to advance new molecules imo at the expense of Otena. The more

[baggerx99]

Street walker; seems your misinformed, my suggestion is for you to start at ground zero of the Antibe story....you may better understand the narrative and timelines associated with all the ups and downs, and ins and outs...will be time well spent

[MrMugsy]

I have to agree. Any fear of Dan should lead you to exit this stock and look for something more comfortable for your investment dollar. I think if you look at the make-up of the development team and the clinical team, you will realize they are not the same people.  There is room for OTENA and for other drug development.  That being said, I absolutely prefer the development team to work

[WalkOverTheStrt]

Bagger, I see what you did on my alias clever.... I think your misinformed as I've held the stock for over five years now and with that a loss on paper over six digits. I don't need your advice on reviewing Antibe's history. I've lived it and it's burned into my memory. I'm stuck with with Dan for better or worse till he actually gets one drug over the line or he plays

[MrMugsy]

OTENA is likely as good as it will get.  Now the clinical team to push it through. Every additional direction will help generate value going forward - but you need to do the exploratory work and that takes time. As for CEOs ... that's one thing I score with much criticism and I'll tell you that what I get from Dan is only available from a handful of  leaders. Most CEOs won'

[WalkOverTheStrt]

Mugsy - Hard disagree with your below statement. Every dollar Atibe spend on other drugs puts greater risk to Otenal until that one is over the finish line. Valuations on pipeline for animal studies and even PH1 (post results) is minor. This is due to the fact that "90% failure rate is for the drug candidates that are already advanced to phase I clinical trial, which does not include the

[MrMugsy]

I've been clear that I don't follow general percentages of success when it comes to OTENA - nor did I ever give up on chronic.  If you think there is only one path or that daily chronic is all we have after acute ... that's just not true ... in my mind anyway. For example - if you had no choice - you could run a strange combination of naproxen and OTENA for improved safety.  

[WalkOverTheStrt]

Mugsy - your point I was in disagreed with was outside Otena pipeline. As in their other pipeline (currently preclinicial) that have for over five years gone no where but the company has spent millions on. I'm fine with them focusing on chronic after a successful PH2 and PH3 of acute as well as their preclinicial drugs but to state that those drugs (chronic which has to be restarted and

[MrMugsy]

Not sure why you think chronic has to go through preclinical but you stay on that path.  That's a conservative way to look at it. I'm more interested in the pipeline and I have been for a very long time - but - I know it requires money.   Regardless - all eyes on P2 acute for now ... with DILIsym work underway for chronic. New molecule to be anounced in the New Year

[MrMugsy]

If you're following, you see that costs are being kept in check.  You have to spend money - no choice in that matter.  That's why they cashed up like they did.  Oh, the whipping the company took for going to market for that much cash - people were blind to the need. Also - you can't say money has been wasted on other drugs.  As we've seen, there's a lot of

[MrMugsy]

If you want to see how chronic advances ... you're going to have to wait for the news releases.  Just like me. I would expect ATE to visit their local FDA office (hahaha) and discuss how acute/chronic move foward in the fastest possible manner.  There will be some negotiations required here - I'm sure - and we could get laughed out of the FDA. I would also expect that we will

[Fairplaymtl]

To my knowledge M. Wallace is not an insider   

[MrMugsy]

You are probably right - and - that is unfortunate for you, me, ATE and for Wallace. Believe it or not ... we all lose. Every - single - one - of - us.

[MrMugsy]

I guess I should clarify ... Over time, we all lose with Wallace retiring. Though I have credible information that says he's recently been around - but - that's neither here nor there. Regardless, Wallace is hanging up that white gown - and - he's washing those beakers out for the last time.  I need to be good with that - and so should you.  IMO.

[Fairplaymtl]

I don't care like that. He is probably liquidating. But he is still around?

[MrMugsy]

Yes - still around but I can't say how active.